Celldex Therapeutics, Inc.
CLDXUnited States
24 filed reports · 205 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
24 reports · Jun 2021 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 16 | 1,754 | Jun 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 1,463 | Dec 2021 to Dec 2025 |
| Current · 8-KSEC EDGAR | 3 | 5 | Jun 2023 to Mar 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 258 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 141 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 1 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 505 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 3 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 154 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 86 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 89 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 244 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 101 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 83 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 6, 2024 | 82 | Open |
Financial data
205 concepts · 3,222 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial196 concepts · 3,086 facts · Dec 2018 to Jul 2026
- Stockholders equity (US GAAP)36 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value33 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents33 · Dec 2018 to Jun 2026
- Net income loss available to common stockholders basic33 · Dec 2019 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax33 · Dec 2019 to Jun 2026
- Allocated share based compensation expense32 · Dec 2019 to Jun 2026
- Cash and cash equivalents at carrying value32 · Dec 2019 to Jun 2026
- Comprehensive income net of tax32 · Dec 2019 to Jun 2026
- Costs and expenses32 · Dec 2019 to Jun 2026
- General and administrative expense (US GAAP)32 · Dec 2019 to Jun 2026
- Interest and other income32 · Dec 2019 to Jun 2026
- Operating income loss32 · Dec 2019 to Jun 2026
- Research and development expense32 · Dec 2019 to Jun 2026
- Revenue32 · Dec 2019 to Jun 2026
- Accretion amortization of discounts and premiums investments31 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect31 · Dec 2019 to Jun 2026
- Depreciation depletion and amortization31 · Dec 2019 to Jun 2026
- Increase decrease in accounts and other receivables31 · Dec 2019 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities31 · Dec 2019 to Jun 2026
- Increase decrease in other operating liabilities31 · Dec 2019 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets31 · Dec 2019 to Jun 2026
- Net cash provided by used in financing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities31 · Dec 2019 to Jun 2026
Segment5 concepts · 64 facts · Dec 2022 to Jun 2026
- Other research and development expense14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Single reportable segment14 · Dec 2022 to Jun 2026
- Supplies expense14 · Dec 2022 to Jun 2026
- Labor and related expense8 · Mar 2024 to Jun 2026
Product1 concepts · 61 facts · Dec 2019 to Jun 2026
- Revenue61 · Dec 2019 to Jun 2026
KPI3 concepts · 11 facts · Dec 2022 to Jun 2026
- Clinical Trial Participants4 · Jun 2023 to Jun 2026
- Countries and Territories Covered4 · Dec 2022 to Jun 2026
- Clinical Trial Sites3 · Dec 2025 to Jun 2026
Segments
125 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 64 facts
- Single Reportable64 · Dec 2022 to Jun 2026
Product or service2 members · 61 facts
- Grant32 · Dec 2019 to Jun 2026
- Service29 · Dec 2019 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.